News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 3276.35 crores during the period ended March 31, 2023
The company has reported total income of Rs. 880.59 crores during the period ended March 31, 2023
The company has reported total income of Rs. 2188.08 crores during the period ended March 31, 2023
The company has reported total income of Rs. 3928.8 crores during the period ended March 31, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
Glucon-D, Sugar Free, EverYuth Scrub, Peel Off Face Mask and Nycil maintained their leadership positions in their respective categories as on March 2023
Subscribe To Our Newsletter & Stay Updated
